Roscovitine targets, protein kinases and pyridoxal kinase

Archive ouverte

Bach, S. | Knockaert, M. | Reinhardt, J. | Lozach, O. | Schmitt, S. | Baratte, B. | Koken, M. | S. P., Coburn | Tang, L. | Jiang, T. | D. C., Liang | Galons, H. | J. F., Dierick | L. A., Pinna | Meggio, F. | Totzke, F. | Schachtele, C. | Lerman, A. S. | Carnero, A. | Wan, Y. | Gray, N. | Meijer, L.

Edité par CCSD ; American Society for Biochemistry and Molecular Biology -

(R)-Roscovitine (CYC202) is often referred to as a "selective inhibitor of cyclin-dependent kinases." Besides its use as a biological tool in cell cycle, neuronal functions, and apoptosis studies, it is currently evaluated as a potential drug to treat cancers, neurodegenerative diseases, viral infections, and glomerulonephritis. We have investigated the selectivity of (R)-roscovitine using three different methods: 1) testing on a wide panel of purified kinases that, along with previously published data, now reaches 151 kinases; 2) identifying roscovitine-binding proteins from various tissue and cell types following their affinity chromatography purification on immobilized roscovitine; 3) investigating the effects of roscovitine on cells deprived of one of its targets, CDK2. Altogether, the results show that (R)-roscovitine is rather selective for CDKs, in fact most kinases are not affected. However, it binds an unexpected, non-protein kinase target, pyridoxal kinase, the enzyme responsible for phosphorylation and activation of vitamin B6. These results could help in interpreting the cellular actions of (R)-roscovitine but also in guiding the synthesis of more selective roscovitine analogs.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion